Singapore - English - HSA (Health Sciences Authority)

b. braun singapore pte ltd - chromium (iii) chloride hexahydrate; copper (ii) chloride dihydrate; iron (ii) chloride tetrahydrate; manganese (ii) chloride tetrahydrate; potassium iodide; sodium fluoride; sodium molybdate dihydrate; sodium selenite pentahydrate; zinc chloride - infusion, solution concentrate - 0.0530mg/10ml - chromium (iii) chloride hexahydrate 0.0530mg/10ml; copper (ii) chloride dihydrate 2.046mg/10ml; iron (ii) chloride tetrahydrate 6.958mg/10ml; manganese (ii) chloride tetrahydrate 1.979mg/10ml; potassium iodide 0.166mg/10ml; sodium fluoride 1.260mg/10ml; sodium molybdate dihydrate 0.0242mg/10ml; sodium selenite pentahydrate 0.0789mg/10ml; zinc chloride 6.815mg/10ml

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - chromic chloride hexahydrate; cupric chloride dihydrate ; ferric chloride hexahydrate ; manganese chloride tetrahydrate ; potassium iodide ; sodium fluoride; sodium molybdate dihydrate ; sodium selenite anhydrous ; zinc chloride - concentrate for soln for inf - n/a - electrolytes in combination with other drugs - electrolytes in combination with other drugs - to meet basal to moderately increased requirements of trace elements in intravenous nutrition

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - chromium trichloride hexahydrate 5.33 µg/ml;  ; copper chloride dihydrate 0.34 mg/ml;  ; ferric chloride hexahydrate 0.54 mg/ml;  ; manganese chloride tetrahydrate 99 µg/ml;  ; potassium iodide 16.6 µg/ml; sodium fluoride 0.21 mg/ml; sodium molybdate dihydrate 4.85 µg/ml;  ; sodium selenite 10.5 µg/ml;  ;  ; zinc chloride 1.36 mg/ml;  ;  ; chromium trichloride hexahydrate 5.33 µg/ml; copper chloride dihydrate 102.3 µg/ml; ferric chloride hexahydrate 540 µg/ml; manganese chloride tetrahydrate 19.79 µg/ml; potassium iodide 16.6 µg/ml; sodium fluoride 210 µg/ml; sodium molybdate dihydrate 4.85 µg/ml; sodium selenite 17.29 µg/ml; zinc chloride 1050 µg/ml - solution for infusion - active: chromium trichloride hexahydrate 5.33 µg/ml   copper chloride dihydrate 0.34 mg/ml   ferric chloride hexahydrate 0.54 mg/ml   manganese chloride tetrahydrate 99 µg/ml   potassium iodide 16.6 µg/ml sodium fluoride 0.21 mg/ml sodium molybdate dihydrate 4.85 µg/ml   sodium selenite 10.5 µg/ml     zinc chloride 1.36 mg/ml     excipient: hydrochloric acid water for injection xylitol active: chromium trichloride hexahydrate 5.33 µg/ml copper chloride dihydrate 102.3 µg/ml ferric chloride hexahydrate 540 µg/ml manganese chloride tetrahydrate 19.79 µg/ml potassium iodide 16.6 µg/ml sodium fluoride 210 µg/ml sodium molybdate dihydrate 4.85 µg/ml sodium selenite 17.29 µg/ml zinc chloride 1050 µg/ml excipient: hydrochloric acid water for injection xylitol - to meet basal to moderately increased requirements of trace elements in parenteral nutrition in adults and children weighing 15 kg and over, when either oral or enteral nutrition is inappropriate

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets, usp are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: spironolactone levels may be exceptiona

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone tablets, usp are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: spironolactone levels may be exceptiona

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone is indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high in this condition. spi

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone is indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high in this condition. spi

United States - English - NLM (National Library of Medicine)

sandoz inc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone tablets, usp are indicated in the management of: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. aldosterone levels may be exceptionally high in this condition. spironolactone is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. for nephrotic patients when treatm

United States - English - NLM (National Library of Medicine)

american health packaging - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232) - spironolactone 25 mg - spironolactone is indicated in the management of: primary hyperaldosteronism for: establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. short-term preoperative treatment of patients with primary hyperaldosteronism. long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. long-term maintenance therapy for patients with bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). edematous conditions for patients with: congestive heart failure: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: aldosterone levels may be exceptionally high in this condition. sp

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

soho flordis international switzerland sa - beta carotene, vitamin b1, vitamin b2, vitamin b6, vitamin b12, vitamin c, vitamin d3, vitamin e, folic acid, biotin, nicotinamide, chromium (chromium chloride), copper (copper sulfate), iron (ferrous fumarate), iodine (potassium iodide), molybdenum (sodium molybdate dihydrate), selenium (sodium selenite), zinc (zinc oxide), magnesium, calcium - tablets film-coated - 2mg+ 1,4mg+ 1,4mg+ 1,9mg+ 2,6mcg+ 85mg+ 200iu (5mcg)+ 15mg+ 600mcg+ 30mcg+ 18mg+ 30mcg+ 1mg+ 27mg+ 200mcg+ 50mcg+ 60mcg+ 11mg+ 53mg+ 150mg